Clinical Trials
20 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05358249 2026-04-14
KontRASt-03
Novartis
Phase 1/2 Active not recruiting
NCT07468071 2026-04-02
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
NCT05907304 2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT03087071 2026-01-12
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02230553 2025-07-08
M14LTK
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT05275374 2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2 Not yet recruiting
NCT03317119 2024-04-08
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
City of Hope Medical Center
Phase 1 Completed
NCT04303403 2023-10-11
Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
National Cancer Centre, Singapore
Phase 1 Unknown
NCT03714958 2023-09-13
TRAHD
Centre Leon Berard
Phase 1 Completed
NCT03428126 2023-06-15
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03668431 2022-06-27
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT02399943 2022-05-16
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT01750918 2021-10-29
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Novartis
Phase 1/2 Completed
NCT02703571 2020-12-21
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT02538627 2017-09-05
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
Merrimack Pharmaceuticals
Phase 1 Terminated